Advertisement

Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

      To provide additional long-term safety and efficacy data in adults with moderate-to-severe atopic dermatitis (AD).
      To read this article in full you will need to make a payment